Edwin R Manuel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4599013/publications.pdf

Version: 2024-02-01

36 papers	1,311 citations	430874 18 h-index	361022 35 g-index
40 all docs	40 docs citations	40 times ranked	2010 citing authors

#	Article	IF	Citations
1	Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Seminars in Cancer Biology, 2019, 59, 236-250.	9.6	200
2	Carbon Nanotubes Enhance CpG Uptake and Potentiate Antiglioma Immunity. Clinical Cancer Research, 2011, 17, 771-782.	7.0	147
3	Systemic Delivery ofSalmonella typhimuriumTransformed with IDO shRNA Enhances Intratumoral Vector Colonization and Suppresses Tumor Growth. Cancer Research, 2012, 72, 6447-6456.	0.9	84
4	Enhancement of Cancer Vaccine Therapy by Systemic Delivery of a Tumor-TargetingSalmonella-Based STAT3 shRNA Suppresses the Growth of Established Melanoma Tumors. Cancer Research, 2011, 71, 4183-4191.	0.9	79
5	Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. Nature Communications, 2020, 11, 6121.	12.8	71
6	Cyclin-dependent kinase inhibitor indirubin-3â€²-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene, 2004, 23, 8206-8215.	5.9	69
7	Effective Cancer Vaccine Platform Based on Attenuated Salmonella and a Type III Secretion System. Cancer Research, 2014, 74, 6260-6270.	0.9	60
8	Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors. Cancer Immunology Research, 2015, 3, 1096-1107.	3.4	58
9	Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice. Clinical Cancer Research, 2012, 18, 5628-5638.	7.0	52
10	TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. Journal of Leukocyte Biology, 2017, 102, 423-436.	3.3	47
11	Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. Cancer Gene Therapy, 2020, 27, 235-245.	4.6	42
12	The helixâ€“loopâ€“helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers. Oncogene, 2004, 23, 1930-1938.	5.9	39
13	Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunology, Immunotherapy, 2011, 60, 99-109.	4.2	38
14	Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model. PLoS ONE, 2016, 11, e0148139.	2.5	38
15	Contribution of T-Cell Receptor Repertoire Breadth to the Dominance of Epitope-Specific CD8 + T-Lymphocyte Responses. Journal of Virology, 2006, 80, 12032-12040.	3.4	28
16	Heterologous Prime/Boost Immunization With p53-based Vaccines Combined With Toll-like Receptor Stimulation Enhances Tumor Regression. Journal of Immunotherapy, 2010, 33, 609-617.	2.4	28
17	Phenotypic Switching of NaÃ¯ve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. Journal of Clinical Medicine, 2019, 8, 1726.	2.4	26
18	Hyaluronidase-Expressing Salmonella Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2020, 19, 706-716.	4.1	26

#	Article	IF	Citations
19	Desmoplasia and oncogene driven acinar-to-ductal metaplasia are concurrent events during acinar cell-derived pancreatic cancer initiation in young adult mice. PLoS ONE, 2019, 14, e0221810.	2.5	18
20	Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses. Virology, 2010, 403, 155-162.	2.4	17
21	5-Azacytidine Potentiates Anti-tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma. Frontiers in Immunology, 2020, 11, 538.	4.8	15
22	Targeting desmoplasia in pancreatic cancer as an essential first step to effective therapy. Oncotarget, 2020, 11, 3486-3488.	1.8	15
23	Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. Biomedicines, 2020, 8, 617.	3.2	14
24	A road less traveled paved by IDO silencing. OncoImmunology, 2013, 2, e23322.	4.6	13
25	Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. OncoImmunology, 2016, 5, e1160184.	4.6	13
26	Clonal Focusing of Epitope-Specific CD8⁺T Lymphocytes in Rhesus Monkeys following Vaccination and Simian-Human Immunodeficiency Virus Challenge. Journal of Virology, 2008, 82, 805-816.	3.4	11
27	Dominant CD8+ T-Lymphocyte Responses Suppress Expansion of Vaccine-Elicited Subdominant T Lymphocytes in Rhesus Monkeys Challenged with Pathogenic Simian-Human Immunodeficiency Virus. Journal of Virology, 2009, 83, 10028-10035.	3.4	10
28	Collagenase-Expressing Salmonella Targets Major Collagens in Pancreatic Cancer Leading to Reductions in Immunosuppressive Subsets and Tumor Growth. Cancers, 2021, 13, 3565.	3.7	10
29	Use of Molecular Beacons for Rapid, Real-Time, Quantitative Monitoring of Cytotoxic T-Lymphocyte Epitope Mutations in Simian Immunodeficiency Virus. Journal of Clinical Microbiology, 2005, 43, 4773-4779.	3.9	9
30	Utilizing Salmonella to treat solid malignancies. Journal of Surgical Oncology, 2017, 116, 75-82.	1.7	7
31	Survivin the battle against immunosuppression. OncoImmunology, 2012, 1, 240-241.	4.6	4
32	Mamu-AâŽ01/Kb transgenic and MHC Class I knockout mice as a tool for HIV vaccine development. Virology, 2009, 387, 16-28.	2.4	2
33	Vaccination Reduces Simian-Human Immunodeficiency Virus Sequence Reversion through Enhanced Viral Control. Journal of Virology, 2010, 84, 12782-12789.	3.4	2
34	Tumor Growth Control with IDO-Silencing Salmonellaâ€"Reply. Cancer Research, 2013, 73, 4592-4593.	0.9	2
35	Developing Effective Salmonella-based Approaches to Treat Pancreatic Cancer. Pancreatic Disorders & Therapy, 2016, 06, 1-2.	0.3	2
36	Diverse Cross-Reactive Potential and VÎ² Gene Usage of an Epitope-Specific Cytotoxic T-Lymphocyte Population in Monkeys Immunized with Diverse Human Immunodeficiency Virus Type 1 Env Immunogens. Journal of Virology, 2009, 83, 9803-9812.	3.4	1